Immune Organoid Platform NextVivo offers an immune-competent human-derived organoid platform for drug and cell therapy development, presenting an opportunity to partner on preclinical testing, platform validation, and collaborative research programs with pharma and biotech companies seeking novel immunotherapies.

Cancer Immunotherapy Focus With initial emphasis on cancer immunotherapies, NextVivo is positioned to engage oncology-focused firms for co-development, licensing deals, or sponsored research that leverages their organoid-based models to accelerate candidate screening and efficacy assessment.

Early Stage Funding Having raised 7.9M in funding and operating as a seed-to-early-stage startup, NextVivo may be receptive to strategic investments, grant collaborations, non-dilutive funding opportunities, or milestone-based partnerships with investors and corporate venture arms.

Academic Ties Originating from Stanford researchers Mark Davis and Calvin Kuo, the company maintains strong academic credibility and access to expert networks, suggesting opportunities for sponsored research, technology licensing, and investigator-initiated study collaborations with academia and biotech consortia.

Small, agile team With a lean team of 2-10 employees, NextVivo may seek strategic collaborations with CROs, contract scientists, or co-development partners to scale projects, accelerate milestones, and manage specialized experiments cost-effectively.